Altimmune begins multinational phase 2 clinical trial of heptcell

 

• Clinical-stage biopharmaceutical company Altimmune (NASDAQ:ALT) announces that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis B (CHB).
• The study is being conducted in the United States, Canada and Europe and is a double-blind, randomized, placebo-controlled study of 80 adult patients with HBeAg-negative inactive CHB and HBsAg ≤ 100 IU/mL.
• There is no cure for CHB, and currently available antiviral medications only control the disease and require life-long treatment.
• https://seekingalpha.com/news/3647866-altimmune-begins-multinational-phase-2-clinical-trial-of-heptcelltm